MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Replicor.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Replicor.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Replicor.com most likely does not offer any adult content.
Popular pages
-
Home | Replicor
Science Overview Replicor is a clinical-stage company developing novel NUCLEIC ACID-BASED POLYMERS (NAPs): oligonucleotides whose antiviral activity is strictly dependent on the polymer chemistry of o...
-
PIPELINE - Replicor
Pipeline Phase II clinical study pipeline The development of an effective treatment for HBV and HBV / HDV infection will require a combination treatment.
-
Replicor announces transition of REP 2139-Mg to subcutaneous administration at AASLD 2021 - Replicor
Replicor announces transition of REP 2139-Mg to subcutaneous administration at AASLD 2021 MONTREAL, November 1st, 2021 – Replicor Inc., a privately held
-
Replicor expands compassionate use of REP 2139-Mg in bulvertide failure patients - Replicor
MONTREAL, June 1st 2022 – Replicor Inc., presented updated clinical data from its expanded compassionate use program for treating chronic HBV / HDV
-
Replicor expands treatment success against HBV and HDV infection with REP 2139-Mg - Replicor
MONTREAL, February 20th, 2023 – Replicor Inc., presented updated clinical data in HBV and HDV infection in a greatly expanded cohort of patients receiving
-
Replicor updates concepts in understanding approaches to functional cure of HBV - Replicor
MONTREAL, May 2nd, 2022 – Replicor Inc., announced the participation of its CSO, Dr. Andrew Vaillant, atthe 2nd Annual CHB Drug Development Congress, held